Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of LY03005 vs Pristiq in Healthy Subjects
NCT03733574Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Jun 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of toludesvenlafaxine in major depressive disorder (MDD) (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Area Under the Concentration-Time Curve at 15 days. Started Jun 2018; status: completed.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03733574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733574.